Davide Fiore Bavaro, Lucia Diella, Alessandra Belati, Carmen Pellegrino, Giuseppina De Vita, Giuseppe Bruno, Mariacristina Poliseno, Irene Francesca Bottalico, Francesco Rosario Paolo Ieva, Federica De Gregorio, Elisabetta Pallara, Chiara Muscatiello, Francesco Di Gennaro, Linda Bussini, Michele Bartoletti, Giovanni Battista Buccoliero, Sergio Lo Caputo, Annalisa Saracino, Sergio Carbonara
In immunocompromised patients with COVID-19, combination therapy appears associated with a lower risk of respiratory failure and may be preferred, when possible, over monotherapy.
INTRODUCTION: COVID-19 is still a potentially serious infection in immunocompromised individuals, with a significant risk of respiratory failure; nevertheless, the optimal treatment strategy is uncertain. Herein, the impact of combination therapy versus monotherapy on risk of respiratory failure was evaluated.
METHODS: This study is a pragmatic target trial emulation performed on observational data collected between 01/01/2022 and 31/03/2024 in 4 tertiary-care hospitals.
PATIENTS: immunocompromised patients with mild/moderate COVID-19.
INTERVENTION: (arm A) monotherapy with antivirals (DAAs) or monoclonal antibodies (MoAbs) versus (arm B) combination therapy of MoAbs plus DAAs.
PRIMARY ENDPOINT: COVID-19-related acute respiratory failure on day 28 post-randomization. Secondary aims: adverse events to therapy, 90-day mortality, 90-day COVID-19 recurrence/complications, and duration of viral shedding.
RESULTS: Overall, 1,035 subjects were screened, and 303 immunocompromised patients were included; main immunodeficiencies were hematologic cancer (71%), exposure to anti-CD20 (36%), solid organ transplantation (15%) and solid cancer (13%). After enrollment, 189 and 114 received mono- or combination therapy, respectively. Of them, 99 patients (33%) met the primary outcome, with a lower incidence in combination therapy group (17% vs. 42%, p < 0.001). In the IPCW-adjusted population, use of combination therapy was associated with a 23.7% (95%CI = 12.4% - 35.1%) reduced risk of developing acute respiratory failure if compared with monotherapy. Results were confirmed at IPCW-adjusted Cox multivariable model: combination therapy was independently associated with a protective effect (aHR = 0.40, 95%CI = 0.22-0.70).
CONCLUSIONS: In immunocompromised patients with COVID-19, combination therapy appears associated with a lower risk of respiratory failure and may be preferred, when possible, over monotherapy.